Newm-035 -

TRG-035 is a monoclonal antibody designed to stimulate the growth of a "third set" of teeth in humans who have lost them due to decay, injury, or congenital conditions.

: Success in Phase I will lead to trials for children aged 2–7 with congenital anodontia (being born without a full set of teeth). Future Outlook NEWM-035

: The drug targets a specific protein called USAG-1 (uterine sensitization-associated gene-1). In nature, USAG-1 acts as a "biological parking brake" that prevents dormant tooth buds in the human jaw from developing into full teeth after the adult set has grown. TRG-035 is a monoclonal antibody designed to stimulate

Below is an overview of the development and science behind . TRG-035: The World's First Tooth Regrowth Drug In nature, USAG-1 acts as a "biological parking

: Preclinical trials on mice and ferrets—chosen for their similar dental structures—successfully produced new teeth with normal enamel and root structures and no significant side effects.

: The treatment is administered via an intravenous injection . By neutralizing USAG-1, the drug reactivates these dormant buds, allowing the body to use its natural BMP and Wnt signaling pathways to form new, functional teeth. Clinical Development and Trials